Screening and diagnosis

Classification and risk stratification

Perioperative care

Quality improvement

Patient education

Nonpharmacologic interventions

Therapeutic procedures

Respiratory support

Follow-up and surveillance

Specific circumstances

Preventative measures

Medical management

Surgical interventions

Inpatient care

Diagnostic procedures

Diagnostic investigations

Insufficient evidence to make a recommendation.

Strongly favor this test or intervention.

The Modified Ann Arbor Classification is a staging system specifically used for non-Hodgkin's lymphoma (NHL). This classification system is used to determine the extent of the disease and to guide treatment decisions. It is based on the number of lymph node regions involved, the presence of extranodal disease, and whether the disease is localized or disseminated. 

The patient population for this calculator includes individuals diagnosed with non-Hodgkin's lymphoma. The clinical utility of the Modified Ann Arbor Classification is to provide a standardized method for staging NHL, which is crucial for prognosis and treatment planning. 

There are no specific exclusion criteria for its use, but it is less applicable to patients with certain types of lymphoma that do not typically present with nodal disease, such as primary cutaneous lymphomas. It is also less useful in the pediatric population, where lymphomas often have different characteristics and behavior compared to adults.

Modified Ann Arbor classification for non-Hodgkin's lymphoma

# Criteria
 ## Lymph node involvement
A. None
B. Single lymph node region
C. >= 2 lymph node regions on the same side of the diaphragm
D. Regional lymph nodes of a single extralymphatic organ/site (with or without other lymph node regions on the same side of the diaphragm)
E. Lymph node regions on both sides of the diaphragm
F. Distant (nonregional) lymph nodes
## Extralymphatic organ/site involvement
G. None
H. Single organ/site
I. Multifocal (disseminated) involvement of >= 1 organs/sites
## Spleen involvement
J. No
K. Yes

# Conditions
- B and G and J
- A and H and J
- C and G and J
- D and H and J
- E and G and J
- E and H and J
- E and G and K
- E and H and K
- (A or B or C or D or E) and I and (J or K)
- F and H and (J or K)
- true

The Lugano Classification is a clinical calculator used for staging lymphoma, specifically Hodgkin and non-Hodgkin lymphomas. This classification system is based on the Ann Arbor staging system with Cotswolds modifications, but includes additional imaging modalities like PET/CT scans. The Lugano Classification provides a standardized method to assess the extent of lymphoma, which is crucial for determining the appropriate treatment strategy and predicting patient prognosis. It takes into account the number of lymph nodes involved, the presence of extranodal disease, and the involvement of organs such as the spleen or liver. The classification does not apply to patients with lymphomas that have a unique staging system, such as primary cutaneous lymphomas, primary CNS lymphomas, and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Lugano classification for staging lymphoma

# Criteria
 ## Nodal involvement
A. Single lymph node region
B. >= 2 regions on the same side of the diaphragm
C. >= 2 regions on both sides of the diaphragm
## Spleen involvement
D. Yes
E. No
## Extranodal involvement
F. Single lesion
G. Noncontiguous (disseminated) involvement of >= 1 sites

# Conditions
- A or (A and E)
- (A and F) or (A and F and E)
- B or (B and E)
- (B and F) or (B and F and E)
- C and E
- (C and F) or (C and D and F)
- C and D
- C and D and F
- G or (G and (A or B or C or D or E)) or (G and A and (D or E)) or (G and B and (D or E)) or (G and C and (D or E))
- true

The Karnofsky Performance Status Scale (KPSS) is a clinical calculator used primarily in patients with cancer. It is a simple, numerical scale that measures a patient's functional status, ability to perform daily activities, and overall quality of life. The KPSS ranges from 0 (indicating death) to 100 (indicating perfect health). 

The clinical utility of the KPSS is to assess a patient's prognosis, determine appropriate treatment strategies, and monitor changes in a patient's condition over time. It is particularly useful in oncology for determining eligibility for certain treatments, such as chemotherapy or surgery, and for predicting survival outcomes. 

There are no specific exclusion criteria for the use of the KPSS. However, it is less useful in patients with non-cancer illnesses or in those with cognitive impairment who may not be able to accurately self-report their functional status.

Karnofsky Performance Scale

# Criteria
 ## Patient description
A. Normal, no complaints, no evidence of disease
B. Able to carry on normal activity, minor signs or symptoms of disease
C. Normal activity with effort, some signs or symptoms of disease
D. Cares for self, unable to carry on normal activity or to do active work
E. Requires occasional assistance but is able to care for most personal needs
F. Requires considerable assistance and frequent medical care
G. Disabled, requires special care and assistance
H. Severely disabled, hospital admission is indicated, death not imminent
I. Very sick, hospital admission necessary, active supportive treatment necessary
J. Moribund
K. Dead

# Conditions
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- true

The Eastern Cooperative Oncology Group (ECOG) performance status, also known as the ECOG score, is a widely used tool in oncology to assess a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.). It is applicable to patients with cancer of any type and at any stage.

The ECOG score ranges from 0 to 5, with 0 indicating fully active and able to carry on all pre-disease activities without restriction, and 5 indicating death. The score is used to determine a patient's prognosis, assess how a disease is progressing, and to determine appropriate treatment strategies. It is also often used in clinical trials to assess eligibility and to monitor patient progress.

There are no specific exclusion criteria for the use of the ECOG score, but it is important to note that it is a subjective measure and may not fully capture a patient's functional status. It is also less useful in patients with fluctuating or rapidly changing conditions.

Eastern Cooperative Oncology Group performance status (ECOG score)

# Criteria
 ## Patient description
A. Fully active, able to carry on all pre-disease performance without restriction
B. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, such as light housework, office work
C. Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours
D. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
E. Completely disabled, cannot carry on any self-care, totally confined to bed or chair
F. Dead

# Conditions
- A
- B
- C
- D
- E
- F
- true

The Modified Glasgow Prognostic Score (mGPS) is a clinical calculator used in the field of oncology to predict the prognosis of patients with cancer. It is applicable to a wide range of cancer types and stages, making it a versatile tool for clinicians. The mGPS is based on two simple, routinely measured inflammatory markers: C-reactive protein (CRP) and albumin levels. 

The clinical utility of the mGPS lies in its ability to stratify patients into different risk groups based on their inflammatory response to cancer. This can guide clinicians in making decisions about treatment strategies and follow-up plans. It can also provide valuable prognostic information to patients and their families.

There are no specific exclusion criteria for the use of the mGPS. However, it should be noted that the score may not be as accurate in patients with concurrent inflammatory or infectious conditions, as these can also affect CRP and albumin levels. Additionally, the mGPS may not be applicable to patients with rare types of cancer or those with very early or very advanced disease, as it has not been extensively validated in these groups.

Modified Glasgow Prognostic Score for cancer outcomes (mGPS)

# Criteria
 ## C-reactive protein
A. <= 10 mg/L
B. > 10 mg/L
## Albumin
C. < 3.5 g/dL [35 g/L]
D. >= 3.5 g/dL [35 g/L]

# Conditions
- A and (C or D)
- B and D
- B and C
- true